ArticleFrontiers in oncology2025

Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report.

Xiaoqing Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.